The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry

Pathology

Volumn 45, Issue 7, 2013, Pages 637-644

  McKelvie, Penelope A ^a   Chan, Fiona ^a   Yu, Yong ^a   Waring, Paul ^b   Gresshoff, Irma ^b   Farrell, Stephen ^a   Williams, Richard A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Competitive PCR; Lymph node recurrences; Papillary thyroid carcinoma; Prognostic factors; Specific BRAFV600E mutation immunohistochemistry

Indexed keywords

B RAF KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896765127     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000008     Document Type: Article

References (49)

1. Sipos JA, Mazzaferri EL Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010; 22: 395-404.
2. Hundahl SA, Fleming ID, Fremgen A.M., et al A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998; 83: 2638-48.
3. Loh KC, Greenspan FS, Gee L, et al Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553-62.
4. Kilfoy BA, Zheng T, Holford T.R., et al International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009; 20: 525-31.
5. Davies L, Welch HG Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-7.
6. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
7. Roring M, Brummer T. Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit Rev Oncog 2012; 17: 97-121.
8. Kim TH, Park YJ, Lim J.A., et al The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-73.
9. Tufano RP, Teixeira GV, Bishop J, et al BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91: 274-86.
10. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
11. Chang H, Lee H, Yoon S.O., et al BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol 2012; 43: 89-95.
12. Capper D, Preusser M, Habel A., et al Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-9.
13. Capper D, Berghoff AS, Magerle M, et al Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-33.
14. Koperek O, Kornauth C, Capper D., et al Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36: 844-50.
15. Haroche J, Charlotte F, Arnaud L., et al High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120: 2700-3.
16. Sahm F, Capper D, Preusser M., et al BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012; 120: e28-34.
17. Andrulis M, Penzel R, Weichert W., et al Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012; 36: 1796-800.
18. Long GV, Wilmott JS, Capper D, et al Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61-5.
19. Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013; 15: 94-100.
20. Feller JK, Yang S, Mahalingam M. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol 2013; 26: 414-20.
21. Skorokhod A, Capper D, von Deimling A, et al Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012; 67: 488-91.
22. Bullock M, O'Neill C, Chou A, et al Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012; 19: 779-84.
23. Bosmuller H, Fischer A, Pham D.L., et al Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immuno-histochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013; 44: 329-35.
24. Preusser M, Capper D, Berghoff A.S., et al Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol 2013; 21: 159-64.
25. Ilie M, Long E, Hofman V., et al Diagnostic value of immunohisto- chemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013; 24: 742-8.
26. Choueiri TK, Cheville J, Palescandolo E., et al BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012; 62: 917-22.
27. O'Neill C.J., Bullock M, Chou A., et al BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010; 148: 1139-45; discussion 45-6
28. Delellis RA, Lloyd RV, Heitz P.U., et al, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004.
29. LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol 2011; 24 (Suppl 2): S1-9.
30. Rivera M, Ricarte-Filho J, Knauf J., et al Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23: 1191-200.
31. Liu J, Singh B, Tallini G., et al Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006; 107: 1255-64.
32. Edge SB, Byrd DR, Compton C.C., et al, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer Verlag, 2010.
33. Yancovitz M, Litterman A, Yoon J., et al Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 2012; 7: e29336.
34. Giannini R, Ugolini C, Lupi C., et al The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3511-6.
35. Vasko V, Hu S, Wu G., et al High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 2005; 90: 5265-9.
36. Gupta S, Ajise O, Dultz L., et al Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 2012; 138: 227-33.
37. Ivanova R, Soares P, Castro P., et al Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immuno-histochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch 2002; 440: 418-24.
38. Elisei R, Ugolini C, Viola D., et al BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-9.
39. Xing M, Alzahrani AS, Carson K.A., et al Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-501.
40. Kim HS, Kim JO, Lee D.H., et al Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. Oncol Rep 2011; 25: 1639-44.
41. Carbonell P, Turpin MC, Torres-Moreno D, et al Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 2011; 13: 467-73.
42. Guerra A, Sapio MR, Marotta V, et al The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 517-24.
43. Guerra A, Fugazzola L, Marotta V., et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012; 97: 2333-40.
44. Gandolfi G, Sancisi V, Torricelli F., et al Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 2013; 98: E934-42.
45. Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 2009; 99: 186-8.
46. Bonnet S, Hartl D, Leboulleux S., et al Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94: 1162-7.
47. Ito Y, Higashiyama T, Takamura Y., et al Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 2007; 31: 2085-91.
48. Eloy C, Santos J, Soares P., et al The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 2011; 459: 265-76.
49. Smith RA, Salajegheh A, Weinstein S., et al Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2011; 42: 500-6.